Overview

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Cerevel Therapeutics, LLC